Table 2.
Details of Surgical Management of the Same 7 Patients Who Underwent Resection After TVEC Therapy, Including Clinical Response to TVEC Therapy, Imaging Findings, Final Pathology and Most Current Disease Status.
| Patient Age at melanoma diagnosis (years) & Sex | Initial size of resected lesion(s) (cm) | Size of lesion(s) at time of resection (cm) | FDG avid on pre-op PET? | FDG avidity (SUV max) of resected lesions on pre-op PET | Goal of resection | Surgical pathology | Time from excision at most recent follow-up and current disease status |
|---|---|---|---|---|---|---|---|
| 74 M | 9.0 × 6.0 | 1.5 × 0.9 | Yes | 4.7 | Render NED | Residual melanoma | 16 months-NED |
| 47 M | 2.5 × 1.5 | 15 × 11 | Yes | 9.5 | Palliation | Residual melanoma | Deceased 1 year post-op |
| 60 M | 1.8 | 1.0 | No | None | Diagnostic + stop TVEC-cost and travel burden | Residual melanoma | Deceased 1 year 8 months post-op due to complications from distant disease |
| 39 M | #1: 1.0 × 0.7 | #1: 0.3 × 0.4 | Yes | 2.5 | Stop TVEC-cost and travel burden | No residual melanoma-2 benign lymph nodes w/follicular and paracortical lymphoid hyperplasia | 2 years, 5 months-alive with distant disease |
| #2: 0.7 × 0.5 | #2: 0.7 × 0.5 | ||||||
| 56 F | #1: 0.9 × 0.6 | #1: 0.6 × 0.6 | Yes | #1: 3.1 | Render NED | No residual melanoma-necrosis with inflammation including granulomatous inflammation compatible with treatment-related changes | 1 year-NED |
| #2: 0.9 | #2: 0.9 × 0.9 | #2: 3.8 | |||||
| #3: 2 cm | #3: 0.7 × 0.9 cm | #3: 1.7 | |||||
| 69 M | #1: 0.8 × 0.7 | #1: 0.4 | Yes | 4.4 | Render NED | Tumoral melanosis with no viable disease identified | <1 month-NED |
| #2: 1.3 × 1.5 | #2: 0.8 | ||||||
| #3: 0.4 × 0.5 | #3: 0.9 | ||||||
| 44 F | #1: 3.7 × 2.5 | #1: 2.5 | Yes | “Increased” | Render NED | Residual melanoma | Continued in-transit disease-undergoing systemic and radiation therapy |
| #2: 0.7 | #2: 1.0 | ||||||
| #3: 0.6 | #3: CR | ||||||
| #4: 0.3 | #4: CR | ||||||
| #5: 2.1 × 0.8 | #5: 0.4 | ||||||
| #6: 0.5 | #6: 0.3 | ||||||
| #7: 0.7 | #7: 0.4 | ||||||
| #8: 0.9 | #8: 0.8 | ||||||
| #9: 2.4 × 1.5 | #9: 1.5 |
Abbreviations: CR, complete response; F, female; FDG, fluorodeoxyglucose; M, male; NED, no evidence of disease; PET, positron emission tomography; SUV, standardized uptake value; TVEC, talimogene laherparepvec.